Isolation of Human Recombinant Therapeutic Monoclonal Anti-Pseudomonas Antibodies
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorUniversity Hospital, Grenoble
About this trial
Pseudomonas aeruginosa is a pathogenic bacteria for human, especially in hospital settings. It can sometimes be multi-resistant to many or even to all antibiotics usually used for its treatment.
The aim of the study is to isolate and produce therapeutic antibodies against the bacteria Pseudomonas aeruginosa in order to provide an alternative treatment to antibiotics in case of infection with an antibiotic-resistant strain of Pseudomonas aeruginosa.
Eligibility criteria
Qualifiers
Patient selected in the retrospective part of the study (patient with serum containing functional anti-Pseudomonas aeruginosa antibodies)
Patient with weight ≥ 32kg.
With a follow-up visit at Grenoble University Hospital with a blood sampling for its care
Having given its written no objection to participate in the prospective phase of this project
Disqualifiers
Legally protected patient (minor, pregnant or nursing woman, ward or ward curated, hospitalized under duress or deprived of liberty)
Trial design
Treatments tested in this trial
- Isolation of anti-Pseudomonas antibodies from type B lymphocytes
Treatment groups
No treatment groups listed
Sponsors and collaborators
Source ClinicalTrials.gov